Genesis MedTech has secured approval from China’s National Medical Products Administration (NMPA) for its antibacterial sutures.
The approval enables the company to immediately introduce absorbable sutures with antibacterial protection in the country.
These sutures are coated with a triclosan antimicrobial agent that exhibits activity against gram-positive and gram-negative bacteria.
They can effectively prevent the growth of methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), Staphylococcus aureus and Staphylococcus epidermidis, thereby substantially decreasing surgical site infection risk.
Genesis MedTech Group chairman and CEO Warren Wang said: “We are thrilled to achieve this significant milestone as the first domestic brand in China to develop antibacterial sutures.
“This pioneering innovation has immense potential to benefit numerous patients. Genesis will introduce more innovative products as part of the company’s roadmap as we continue our mission to make quality healthcare more accessible for patients worldwide.”
In September of last year, the company received NMPA approval for its barbed sutures.
The company’s barbed absorbable sutures with black needles, non-absorbable surgical polypropylene sutures and controlled-release needle sutures are already in use in several hospitals.
Surgical site infections are commonly reported hospital-acquired infections that are linked to significant clinical and economic challenges.
The Centers for Disease Control and Prevention and the World Health Organization have provided guidelines for preventing surgical site infections.
These authoritative institutions have suggested the use of antimicrobial agent-coated sutures to reduce the risk of surgical site infections in various types of surgeries.
Headquartered in Singapore, Genesis focuses on providing multi-therapy medical device products for emerging markets.